[go: up one dir, main page]

MX2015012109A - Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso. - Google Patents

Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso.

Info

Publication number
MX2015012109A
MX2015012109A MX2015012109A MX2015012109A MX2015012109A MX 2015012109 A MX2015012109 A MX 2015012109A MX 2015012109 A MX2015012109 A MX 2015012109A MX 2015012109 A MX2015012109 A MX 2015012109A MX 2015012109 A MX2015012109 A MX 2015012109A
Authority
MX
Mexico
Prior art keywords
oral pharmaceutical
methods
pharmaceutical composition
sulfate salts
tablets
Prior art date
Application number
MX2015012109A
Other languages
English (en)
Other versions
MX377525B (es
Inventor
Edmund V Dennett Jr
David S Wells
Original Assignee
Braintree Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Braintree Lab filed Critical Braintree Lab
Publication of MX2015012109A publication Critical patent/MX2015012109A/es
Publication of MX377525B publication Critical patent/MX377525B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01D—COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
    • C01D5/00—Sulfates or sulfites of sodium, potassium or alkali metals in general
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención generalmente se dirige a una composición para un comprimido farmacéutico oral que comprende una sal de sulfato, por ejemplo, sulfato de sodio, en donde la composición se puede administrar por ingestión oral directa y por desintegración en agua antes de la ingesta oral; la presente invención se dirige adicionalmente al uso de dichas formulaciones para un comprimido farmacéutico oral para inducir la laxación o para tratar o prevenir la constipación.
MX2015012109A 2013-03-15 2014-03-14 Composición farmacéutica oral de sales sulfato para comprimidos de uso dual y métodos para su uso. MX377525B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361798759P 2013-03-15 2013-03-15
PCT/US2014/028805 WO2014144407A1 (en) 2013-03-15 2014-03-14 Dual use oral pharmaceutical composition tablets of sulfate saltes and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2015012109A true MX2015012109A (es) 2016-04-15
MX377525B MX377525B (es) 2025-03-10

Family

ID=50680164

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012109A MX377525B (es) 2013-03-15 2014-03-14 Composición farmacéutica oral de sales sulfato para comprimidos de uso dual y métodos para su uso.

Country Status (25)

Country Link
US (2) US9919007B2 (es)
EP (2) EP2968174B1 (es)
JP (2) JP6441890B2 (es)
CN (2) CN105142617B (es)
AU (3) AU2014227598B2 (es)
BR (1) BR112015019776A2 (es)
CA (1) CA2903283C (es)
CY (1) CY1122387T1 (es)
DK (1) DK2968174T3 (es)
EA (2) EA201992382A3 (es)
ES (1) ES2764462T3 (es)
HK (1) HK1214519A1 (es)
HR (1) HRP20192227T1 (es)
HU (1) HUE046754T2 (es)
IL (1) IL241367A0 (es)
LT (1) LT2968174T (es)
ME (1) ME03656B (es)
MX (1) MX377525B (es)
PE (1) PE20151543A1 (es)
PL (1) PL2968174T3 (es)
PT (1) PT2968174T (es)
RS (1) RS59667B1 (es)
SI (1) SI2968174T1 (es)
SM (1) SMT201900716T1 (es)
WO (1) WO2014144407A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9919007B2 (en) 2013-03-15 2018-03-20 Braintree Laboratories, Inc. Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof
WO2016040733A1 (en) * 2014-09-12 2016-03-17 Braintree Laboratories, Inc. Sulfate salt solution laxative compositions and methods of use thereof
US11007170B2 (en) 2017-02-02 2021-05-18 Panaxia Pharmaceutical Industries Ltd. Composition for buccal or sublingual administration of cannabis extract and methods for making same
US10143656B1 (en) 2017-08-04 2018-12-04 Braintree Laboratories, Inc. Solid oral sulfate salt formulations for cleaning a colon and methods of using same
WO2022093170A1 (en) * 2020-10-26 2022-05-05 Braintree Laboratories, Inc. Sulfate salt formulations for colon cleansing
CN116509809B (zh) * 2023-04-19 2024-12-03 山东齐都药业有限公司 复方硫酸钠片剂及其制备方法与应用
US12239659B2 (en) 2023-06-15 2025-03-04 Braintree Laboratories, Inc. Methods of administering safe colon cleansing compositions

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873694A (en) 1973-09-27 1975-03-25 Cpc International Inc Direct compression tabletting composition and pharmaceutical tablets produced therefrom
JPS5438167B2 (es) 1974-04-27 1979-11-19
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
GB2058565B (en) 1979-09-21 1983-12-07 Leo Pharm Prod Ltd Layer tablets
NZ198241A (en) 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
DE3134591A1 (de) 1981-09-01 1983-03-10 Bayer Ag, 5090 Leverkusen Neue arzneimittelpraeparationen fuer glykosidhydrolasen-inhibitoren
JPS5839618A (ja) 1981-09-04 1983-03-08 Chugai Pharmaceut Co Ltd 持続性積層錠剤
EP0080862B1 (en) 1981-12-02 1985-09-25 Beecham Group Plc Pharmaceutical formulation comprising beta-lactam antibiotics
JPS59101423A (ja) 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
JPS6097919A (ja) 1983-11-01 1985-05-31 Furointo Sangyo Kk 圧縮成形用賦形剤の製造方法
NL8400911A (nl) 1984-03-22 1985-10-16 Dagra Nv Werkwijze ter bereiding van een farmaceutische toedieningsvorm die tetracycline of doxycyclinezouten bevat.
AU6196786A (en) 1985-08-01 1987-03-05 Braintree Laboratories Inc. Low-sodium laxative and lavage formulation
US4753801A (en) 1985-10-25 1988-06-28 Eli Lilly And Company Sustained release tablets
DE3887179T2 (de) * 1987-03-02 1994-06-16 Brocades Pharma Bv Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
IL86859A (en) 1987-07-10 1991-12-15 E Z Em Inc Aqueous cathartic solution containing inorganic salts
NO168563C (no) 1987-09-28 1992-03-11 Collett Marwell Hauge As Anvendelse av en organoleptisk akseptabel blanding av magnesiumsalter som mineraladditiv
US4837030A (en) 1987-10-06 1989-06-06 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
JPH0194937A (ja) * 1987-10-06 1989-04-13 Yokohama Yushi Kogyo Kk 微粉状ミネラル類の被覆物の製造方法
US5211958A (en) 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
AU2900889A (en) 1987-12-24 1989-07-19 Thomas Julius Borody Orthostatic lavage solutions
WO1989009604A1 (en) 1988-04-05 1989-10-19 Dale Driver Dietary mineral sulfur supplement
JPH0816061B2 (ja) 1988-07-13 1996-02-21 森下ルセル株式会社 腸管洗浄液用組成物と腸管洗浄液
IT1229568B (it) 1989-04-17 1991-09-04 Giuliani Spa Composizione farmaceutica per uso orale adatta all'impiego nel lavaggio gastro intestinale, in particolare per uso diagnostico, oppure come lassativo catartico.
US5654003A (en) * 1992-03-05 1997-08-05 Fuisz Technologies Ltd. Process and apparatus for making tablets and tablets made therefrom
BR9306063A (pt) 1992-03-11 1997-11-18 Procter & Gamble Composições mistas de bebida de psylium que contém base granulada
WO1994012191A1 (en) 1992-11-24 1994-06-09 Block Drug Company, Inc. Pharmaceutical compositions for use in gastrointestinal washes
US5958458A (en) 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
US5498425A (en) 1995-03-17 1996-03-12 Block Drug Company, Inc. Phosphosoda buffered saline laxative
US5710183A (en) 1995-07-14 1998-01-20 Halow; George M. Laxative/antidiarrheal composition comprising polyethylene glycol and fiber bulking agent
AUPN634595A0 (en) 1995-11-03 1995-11-30 Borody, Thomas Julius Improved method for colonic evacuation
DE69627170T2 (de) 1996-05-08 2004-03-04 Aronchick, Graig A. Nichtwässrige abführmittel für den kolon
US6162464A (en) 1997-03-31 2000-12-19 Inkine Pharmaceutical, Inc. Non-aqueous colonic purgative formulations
AU745361B2 (en) 1997-04-18 2002-03-21 Janssen Pharmaceutica N.V. Use of 5HT3 antagonists for promoting intestinal lavage
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6350470B1 (en) 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
WO2000025744A1 (en) 1998-10-30 2000-05-11 Mcneil-Ppc, Inc. Granular, free-flowing pharmaceutical composition, and straw-like dosage form for oral administration thereof
US6645481B1 (en) 2000-09-28 2003-11-11 Braintree Laboratories, Inc. Method of achieving overnight laxation and control of bowel function
US6887492B2 (en) 2000-12-14 2005-05-03 Leiner Health Services Corp. Magnesium plus interactive agent delivery
AUPR590701A0 (en) 2001-06-25 2001-07-19 Colocaps Pty Ltd Laxative preparation
AUPS088702A0 (en) 2002-03-04 2002-03-28 Borody, Thomas Julius Electrolyte purgative
US6946149B2 (en) 2002-04-30 2005-09-20 Braintree Laboratories, Inc. Salt solution for colon cleansing
US20040071779A1 (en) 2002-10-09 2004-04-15 Keiser Dale Arthur Gelled laxative compositions
US7291324B2 (en) 2002-10-22 2007-11-06 Braintree Laboratories Inc. Method of bowel cleansing
GB0224909D0 (en) 2002-10-25 2002-12-04 Norgine Europe Bv Colon cleansing compositions
PL1663257T3 (pl) 2003-07-09 2009-08-31 Braintree Laboratories Inc Zastosowanie środków przeczyszczających do leczenia zespołu jelita drażliwego
US7687075B2 (en) 2003-11-19 2010-03-30 Salix Pharmaceuticals, Ltd. Colonic purgative composition with soluble binding agent
GB0409104D0 (en) 2004-04-23 2004-05-26 Norgine Europe Bv Compressed pharmaceutical compositions
CA2569178A1 (en) 2004-06-04 2005-12-22 Braintree Laboratories, Inc. Method of bowel cleansing
WO2007013093A2 (en) 2005-04-01 2007-02-01 Shiv Prakash Laxative formulation containing a triphala extract
WO2006118562A1 (en) 2005-04-29 2006-11-09 Inkine Pharmaceutical Company, Inc. Purgative composition and uses thereof
JP5276435B2 (ja) 2005-05-06 2013-08-28 セイリックス ファーマシューティカルズ， インコーポレイティッド ポリエチレングリコールの結腸の下剤組成物
US20070087056A1 (en) 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US20070082061A1 (en) 2005-10-07 2007-04-12 Nelson Ayala Reduction of saltiness with sweeteners
DK1976520T3 (da) 2005-12-29 2011-06-27 Braintree Lab Et sæt omfattende et osmotisk laksativ og et stimulerende laksativ til forberedelse af kolon til virtuel kolonskopi
US8067033B2 (en) * 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US7998510B2 (en) 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
NZ580999A (en) 2007-05-17 2012-05-25 David Lubowski Combination laxative compositions comprising a colonic stimulant and a bulking laxative
EP2211838A2 (en) 2007-10-17 2010-08-04 Thomas Jefferson University Bowel purgative and uses thereof
JP2011510020A (ja) 2008-01-16 2011-03-31 ブレーントリー ラボラトリーズ インコーポレーティッド 硫酸塩による予防法および治療法
US20090258090A1 (en) 2008-04-11 2009-10-15 Braintree Laboratories, Inc. Colon cleansing solution
WO2009137672A1 (en) 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
US20100255122A1 (en) 2009-04-02 2010-10-07 Garren Mary L Edible gelatin bowel preparation and bowel cleansing method
JP5759450B2 (ja) 2009-04-21 2015-08-05 バックウィッチ, デール, アール.BACHWICH, Dale, R. 大腸洗浄システム
US20100285164A1 (en) * 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
GB0912487D0 (en) 2009-07-17 2009-08-26 Norgine Bv Improvements in and relating to colon cleansing compositions
GB0913295D0 (en) 2009-07-30 2009-09-02 Norgine Bv Improvements in and relating to pharmaceutical compositions
WO2011110347A2 (en) 2010-03-10 2011-09-15 Giuliani International Limited Compositions for colon lavage and methods of making and using same
EP2544543A1 (en) 2010-03-12 2013-01-16 Scott Cordray Method of treatment
JP5665372B2 (ja) * 2010-06-02 2015-02-04 旭化成ケミカルズ株式会社 速崩壊性固形製剤
EP2598123A1 (en) * 2010-07-27 2013-06-05 Norgine BV Compositions
SG190018A1 (en) 2010-11-04 2013-06-28 Norgine Bv Formulations comprising polyethylene glycol
MX355760B (es) 2010-12-13 2018-04-27 Salix Pharmaceuticals Inc Formulaciones gástricas y colónicas y métodos para elaborar y usar las mismas.
WO2012091049A1 (ja) * 2010-12-28 2012-07-05 大鵬薬品工業株式会社 口腔内崩壊錠剤
CA2825808C (en) 2011-01-28 2020-09-01 William A. Shaver Method, composition and package for bowel cleansing
DE202012013349U1 (de) 2011-01-31 2016-06-27 Norgine Bv Verbesserungen bei und bezüglich Zusammensetzungen
TWI535461B (zh) 2011-03-11 2016-06-01 諾金私人有限公司 結腸清潔溶液、用於製備該溶液之組成物、包含該組成物或溶液之套組、與製備該溶液之方法
JP2014513085A (ja) 2011-04-15 2014-05-29 ブレーントリー ラボラトリーズ インコーポレーティッド 通過時間エンハンサーとしての硫酸塩
US8778907B2 (en) 2011-04-27 2014-07-15 Cumberland Pharmaceuticals Lactulose for bowel evacuation
WO2013044085A1 (en) 2011-09-23 2013-03-28 Subramanian Veerappan Sellappan A solid, edible, chewable laxative composition
IN2014DN03373A (es) 2011-10-27 2015-06-05 Borody Thomas J
US9149493B2 (en) 2011-11-28 2015-10-06 Alfa Wassermann Spa Compositions for bowel cleansing and use thereof
HK1212222A1 (en) 2012-08-29 2016-06-10 Salix Pharmaceuticals, Inc. Laxative compositions and methods for treating constipation and related gastrointestinal diseases and conditions
LT2895163T (lt) 2012-09-11 2019-06-25 Norgine Bv Kompozicijos, apimančios peg ir askorbatą
US20140087007A1 (en) 2012-09-27 2014-03-27 Braintree Laboratories, Inc. Bowel cleansing preparations
US9919007B2 (en) 2013-03-15 2018-03-20 Braintree Laboratories, Inc. Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof

Also Published As

Publication number Publication date
HUE046754T2 (hu) 2020-03-30
EP2968174A1 (en) 2016-01-20
AU2014227598B2 (en) 2018-12-06
LT2968174T (lt) 2020-01-10
IL241367A0 (en) 2015-11-30
SMT201900716T1 (it) 2020-01-14
JP2019023244A (ja) 2019-02-14
EA201992382A3 (ru) 2020-05-31
CY1122387T1 (el) 2020-11-25
ME03656B (me) 2020-07-20
SI2968174T1 (sl) 2020-02-28
US20160030473A1 (en) 2016-02-04
PT2968174T (pt) 2020-01-15
CN105142617B (zh) 2018-08-03
CN108904462A (zh) 2018-11-30
JP6441890B2 (ja) 2018-12-19
PE20151543A1 (es) 2015-11-29
BR112015019776A2 (pt) 2017-07-18
WO2014144407A1 (en) 2014-09-18
EP3563838A1 (en) 2019-11-06
WO2014144407A8 (en) 2014-11-20
HRP20192227T1 (hr) 2020-02-21
DK2968174T3 (da) 2019-12-16
EP2968174B1 (en) 2019-10-16
RS59667B1 (sr) 2020-01-31
JP2016514677A (ja) 2016-05-23
EA201591568A1 (ru) 2015-12-30
EA201992382A2 (ru) 2020-02-28
US20180207200A1 (en) 2018-07-26
CN105142617A (zh) 2015-12-09
CA2903283A1 (en) 2014-09-18
AU2020213378A1 (en) 2020-08-27
AU2014227598A1 (en) 2015-08-27
ES2764462T3 (es) 2020-06-03
PL2968174T3 (pl) 2020-05-18
CA2903283C (en) 2023-09-05
JP6724114B2 (ja) 2020-07-15
MX377525B (es) 2025-03-10
US9919007B2 (en) 2018-03-20
HK1214519A1 (zh) 2016-07-29
EA034234B1 (ru) 2020-01-20
AU2019201511A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
MX2015012109A (es) Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
BR112014014341A2 (pt) Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica
GT201400069A (es) Composiciones farmaceuticas
BR112015012197A8 (pt) usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos
BR112015020466A8 (pt) inibidores de cdc7, seus usos, e composição farmacêutica
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
MX2019007956A (es) Liberacion autorregulada de ingrediente farmaceutico activo.
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
CL2016000950A1 (es) Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2.
BR112016004358A8 (pt) combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
BR112014004732A2 (pt) composto benzotiazolona
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
CL2007000485A1 (es) Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina.
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
BR112015030350A2 (pt) forma de dosagem farmacêutica oralmente administrável para uso na prevenção e/ou no tratamento de uma doença cardiovascular
CO2018009543A2 (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma
CO6592037A2 (es) Combinación de un aine y un aminoacido
AR097890A1 (es) Compuestos de urea
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida

Legal Events

Date Code Title Description
FG Grant or registration